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Pertussis-like toxins are secreted by several bacterial patho-
gens during infection. They belong to the AB5 virulence factors,
which bind to glycans on host cell membranes for internaliza-
tion. Host cell recognition and internalization are mediated by
toxin B subunits sharing a unique pentameric ring-like assem-
bly. Although the role of pertussis toxin in whooping cough is
well-established, pertussis-like toxins produced by other bacte-
ria are less studied, and their mechanisms of action are unclear.
Here, we report that some extra-intestinal Escherichia coli patho-
gens (i.e. those that reside in the gut but can spread to other bodily
locations) encode a pertussis-like toxin that inhibits mammalian
cell growth in vitro.We found that this protein, EcPlt, is related to
toxins produced by both nontyphoidal and typhoidal Salmonella
serovars.Pertussis-like toxinsaresecretedasdisulfide-bondedhet-
erohexamers in which the catalytic ADP-ribosyltransferase sub-
unit is activated when exposed to the reducing environment in
mammalian cells. We found here that the reduced EcPlt exhibits
large structural rearrangements associated with its activation.We
noted that inhibitory residues tethered within the NAD-binding
site by an intramolecular disulfide in the oxidized state dissociate
upon the reduction and enable loop restructuring to form the
nucleotide-binding site. Surprisingly, although pertussis toxin tar-
gets a cysteine residue within the  subunit of inhibitory trimeric
G-proteins,weobserved that activatedEcPlt toxinmodifies aprox-
imal lysine/asparagine residue instead. In conclusion, our results
reveal the molecular mechanism underpinning activation of per-
tussis-like toxins, and we also identified differences in host target
specificity.
Pathogenic Escherichia coli strains preferentially inhabit dif-
ferent sites within their hosts, with enteric or extra-intestinal
niches presenting distinctly different challenges. Infection by
enteric or diarrheagenic E. coli can result in gastroenteritis, but
it seldom spreads beyond the intestinal tract except in immu-
nocompromised individuals (1, 2). In contrast, extra-intestinal
E. coli (ExPEC)7 strains such as uropathogenicE. coli (UPEC) or
neonatal meningitis E. coli can reside passively within the gut
until conditions permit their expansion into the urinary tract,
blood, or nervous systemwhere theymay potentially cause life-
threatening disease (3). To do so, ExPEC strains express a range
of virulence factors, often encoded onmobile genetic elements,
including AB5 toxins. Such phage-encoded toxins are secreted
by severalmajor bacterial pathogens, including enterotoxigenic
E. coli (55) and enterohemorrhagic E. coli (4); Vibrio cholerae
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(5), Shigella (6), Salmonella (7), and Bordetella pertussis (8, 9).
Modern sequencing techniques frequently identify novel AB5
toxins related to those previously studied, but their conserva-
tion at the level of function remains to be determined.
AB5 virulence factors bind to glycans present on the sur-
face of eukaryotic host cell membranes resulting in their
internalization. Once inside the host cell, the enzymatic A
subunits are released allowing them to disrupt host bio-
chemistry and physiology. Host cell recognition and inter-
nalization are mediated by the toxin B subunits that share a
unique pentameric ring-like assembly. This juxtaposes with
the A subunit cargos that are class-specific and structurally
divergent, and their activation inside mammalian cells
occurs through distinct intracellular detection and release
mechanisms (10). Five AB5 toxin families currently exist: the
enzymatic components of the subtilase cytotoxin (11) and
EcxAB toxin (12) are proteases, whereas those of the Shiga
group (6) are ribosome inhibitors; cholera and heat-labile
enterotoxins (4, 5) carry related ADP-ribosyltransferases, as
do the related pertussis (8, 9) and typhoid toxin (7) proteins.
Toxin ADP-ribosyltransferases (ARTs) hydrolyze the nico-
tinamide group from NAD and transfer the ADP-ribose moi-
ety onto specific host proteins. Pertussis toxin specifically tar-
gets inhibitory trimeric G-proteins by modifying a conserved
cysteine located four residues from the C termini of the G
subunit (13). This modification renders the Gi/o subunits
unable to associate with their cognate G-protein-coupled
receptors (GPCRs) thus modulating the host’s immune re-
sponse. A series of related pertussis-like (Plt) toxins exist within
the genomes of pathogenic bacteria, including strains of E. coli,
Salmonella, and Yersinia. The bacterial strains harboring such
virulence factors are diverse, and their evolutionary relation-
ship is complicated due to the spread of these genes on mobile
genetic elements. Proteins within the Plt family include the
atypical archetype member whose glycan-binding B subunits
have expanded and diverged within the B. pertussis genome
to form four separate genes yielding a pseudopentameric
glycan-binding platform. In contrast, other pertussis-like
toxins display a homopentameric glycan-binding stoichiom-
etry. All Plt proteins nonetheless carry a conserved catalytic
A subunit.
In the secreted state, the enzymatic ART domain of per-
tussis-like toxins lies atop the five glycan-binding subunits
allowing its C terminus to thread through a U-shaped
NAD-binding cleft before plunging into the pore of the B
subunit pentamer (7, 9). When these C-terminal residues are
truncated from pertussis toxin, its ART domain is constitu-
tively active in vitro but is unable to associate with its pseu-
dopentamer or enter cells (14). Enzymatic activation in vivo
requires proteolytic separation of the inhibitory C terminus
and reduction of a connecting disulfide. Although the
molecular mechanisms underlying an alternative activation
mechanism of cholera toxin are understood (15), the
changes that occur following activation of a pertussis-like
protein have not previously been characterized.
Although the association of pertussis toxin with whooping
cough is well-established, orthologous pertussis-like toxins
present within other pathogenic bacterial infections are less
studied, and their mechanism(s) of action are unclear (7).
Here we identify a pertussis-like AB5 protein (EcPltAB) from
clinical E. coli isolates that is related to the typhoid and
ArtAB toxins observed in typhoidal and nontyphoidal Sal-
monella serovars. We provide structures that confirm that
pertussis-like toxins are secreted as inactive forms in which
an intramolecular disulfide holds an occluding C-terminal
tail within the NAD-binding site. This conserved disulfide
also serves as a redox switch that senses host cell entry, with
reduction of the bond allowing displacement of the occlud-
ing C-terminal residues, facilitating NAD binding andmat-
uration of catalytic activity. At a global level, the existence of
EcPltAB-type proteins, and their relatives (55) expands the
family of known bacterial pertussis-like toxins capable of
modulating the human immune system. Furthermore, we
show that although AB5 proteins are segregated into evolu-
tionarily related enzyme families, these may not always mod-
ify the same residues within host proteins.
Results
Identification of EcPltAB
The frequency with which pathogenic bacterial strains are
isolated from clinical settings does not necessarily correlate
with their representation in genomic databases, yet it remains a
useful proxy measure. We thus determined the prevalence of
genes encoding AB5-type toxins among complete and draft
E. coli genome sequences available on the NCBI database.
E. coli genomes were queried using previously identified A and
B subunit sequences. As expected, most genes discovered cor-
responded to previously known E. coli toxins; by far the most
prevalent were the Shiga toxins produced by Shiga toxigenic
E. coli, proteins whose action can cause hemolytic-uremic syn-
drome following infection, identified in 19% of genomes (sup-
plemental Fig. S1). The next most prevalent were toxins from
the cholera family LT-I and LT-II heat-labile enterotoxins
secreted by enterotoxigenic E. coli (Fig. 1), identified in8% of
the genomes. The properties of these enteric E. coli toxins are
well-established (4, 5, 11).However, the thirdmost common set
of AB5 genes identified was a series of related pertussis-like
proteins found in ExPEC genomes, particularly from phylo-
group B2 (Fig. 1). The B subunit of these toxins shared 69%
sequence identity to ArtB and the upstream A subunit 70%
identity to ArtA, two components of a pertussis-like toxin pro-
duced by Salmonella typhimurium DT104 (16). In contrast to
these Salmonella and Escherichia orthologs, the archetype per-
tussis toxin has an expanded set of four glycan-binding B sub-
units (named S2–S5) associated with a single catalytic A or S1
subunit. The Salmonella ArtAB protein is an active ADP-ribo-
syltransferase (17), whereas a related typhoid toxin additionally
serves as a cargo carrier for an accessory cytolethal distending
toxin (7). Our analysis indicates that the E. coli Plt toxins are
more evolutionarily diverse than the currently identified Sal-
monella variants, with at least three semi-separate lineages
sharing between 70 and 80% sequence identity. We refer to the
product of these pertussis-like genes as E. coli-pertussis-like
toxins (EcPlt).
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Cytotoxicity of EcPltAB
We characterized the EcPlt toxin family by cloning a number
of representativemembers and expressing themusing standard
recombinant techniques, focusing primarily on the EcPlt genes
(E9YZW8 and E9YZW9) cloned from UPEC isolate PA26B.
The oxidized EcPltAB holotoxin was purified after co-express-
ing both subunits using a periplasmic expression system (18).
The 96-kDa soluble protein complex eluted on gel filtration
with a molecular mass consistent with that of an AB5 hetero-
hexameric stoichiometry. To ascertain whether this holotoxin
was functional, it was added to human embryonic kidney
(HEK293T) or African green monkey kidney epithelial cells
(Vero). Mammalian cell lines grown to 40–50% confluency
were exposed to different concentrations of EcPltAB (Fig. 2a
and supplemental Fig. S2). The characteristic response profile
of pertussis toxin involves a slow cellular entry mechanism fol-
lowed by an accumulative interruption of signaling resulting in
clustered growth (19). Over an 18-h period, control-treated
cells remained unaffected and continued to proliferate,
although those exposed to EcPltAB displayed cell clustering
and an absence of growth (see supplemental Fig. S2, a–c) com-
pared with buffer-alone controls (supplemental Fig. S2d).
Next, we performed a glycan array analysis to determine the
specificity ofEcPltAB (see supplemental Table S1). Its B subunit
displayed avidity for a broad range of branched eukaryotic gly-
cans, especially those with N-acetylneuraminic acid (Neu5Ac)
termini, thus implying EcPlt targets a similar range of cell types
as typhoid toxin (7).
We next sought to establish which eukaryotic proteins were
targeted by EcPltA. The EcPltA toxin shares 50–70% identity
with Salmonella ArtA proteins and 31% identity with the per-
tussis toxin’s catalytic S1 subunit, two known ADP-ribosyl-
transferases that modify the  subunits of inhibitory trimeric
GTP-binding proteins (17, 20). We set up an assay to identify
equivalentEcPltA substrates by using biotin-conjugatedNAD
as substrate for the toxins. In such assays, ADP-ribosylation
also adds a biotin tag to protein substrates that can then be
imaged by Western blotting using streptavidin-horseradish
peroxidase.Holotoxin (EcPltABor PT) versions of this assay are
dependent upon toxin activation and ADP-ribosylation rate,
althoughwhen the assay is performedwith constitutively active
proteins (EcPltA or PT S1), only the ADP-ribosylation rate is
measured.
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Figure 1. E. coli AB5 toxins. Shown is a cladogram of AB5 toxin sequences identified in genome sequenced E. coli strains available on the NCBI database.
Archetype sequences from thequeryingdataset are indicatedwith anasterisk. E. coli strains harboringmore thanoneAB5 group are indicatedby a red star. The
inner circle represents the E. coliphylogenetic groups (A, B1, B2, andD). Additional color-coded circles indicate the place, year, and source of each strain, aswell
as the associated infection (where known). Because Shiga toxigenic E. coli strains are over-represented in the NCBI database, only archetypical Shiga toxin
variants are presented. The EcPltA toxin focused on in this study is highlighted with a blue star. A schematic of the A and B subunit domain displayed with the
positions of the intramolecular disulfides (yellow) and the inhibitory C terminus (pink) is at the bottom of the figure. Inset, an expanded view of the pertussis
toxin branch. A complete overview of all Shiga toxin variants and their associated strains is presented in supplemental Fig. S1.
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Using radiolabeled substrate, other groups (20) have shown
that the PT holotoxin is activated by the presence of ATP and
reducing agents. Our ownADP-ribosylation assay recapitulates
this result with a 41-kDa band being modified by PT in crudely
purified trimeric G-protein brain extracts or Vero cell lysates
under identical conditions (Fig. 2). A similar bandwas observed
in reactions containing the EcPltAB holotoxin (Fig. 2). In both
reactions, a major band at 41 kDa was ADP-ribosylated and
migrated close to the molecular weight of PT-treated Gi pro-
teins (Fig. 2b, left panel). To confirm that EcPltA targeted Gi
subunits, we cloned two HsGi3 constructs (the most readily
expressed isoform): the full-length protein and a more soluble
construct lacking the N-terminal aliphatic helix (HsGi3N).
Following expression and purification, full-lengthHsGi3 acted
as substrate for the toxin’s ADP-ribosyltransferase activity and
migrated at a similar molecular weight to a band modified in
Vero cell extracts, whereas other proteins within the Coomass-
ie-stained lysate did not (Fig. 2b, right panel). Both the full-
length protein and Gi3 N-mutant served equally well as sub-
strates for PT orEcPlt (supplemental Fig. S3), the latterGi3N
construct was favored for routine assays due to its enhanced
stability.
PT is responsible for many of the pathogenic features of
B. pertussis. However, other Bordetella species also contain
Figure 2. Cytotoxicity of recombinant EcPltAB. 18 h after treatment with buffer or different concentrations of EcPltAB, Vero cells were stained and imaged.
a, representative images foruntreatedcontrols (left) and50ng/mlEcPltAB (right) are shown.b, ADP-ribosyltransferaseassays inwhichpertussis toxinor EcPltAB
were used to modify different protein substrates, including trimeric G-protein extracts, recombinant human Gi3, or Vero cell lysates. Reactions at 37 °C were
performed in the presence of biotin-NAD and then quenched after 5min, separated by SDS-PAGE, transferred to aWestern blottingmembrane, and imaged
with either luminescence following streptactin-HRP exposure (left) or Coomassie (right). c,Western blottings showing the incubation of ExPEC culturemedium
withNAD-biotinwith andwithout the presence ofHsGi3N. d, Vero cellswere imaged in a similarmanner to those in aweremonitored for the degree of cell
growth relative to buffer controls following exposure to different concentrations of EcPltAB or A subunit mutants. Surface area is calculated from the percent-
age of each image stained by crystal violet. Data represent the mean S.D. from three replicates.
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ptx-like genes yet fail to produce the toxin because of inactive
promoters (21). Using our assay, we sought to identify whether
ADP-ribosyltransferase activity was detectable in the superna-
tant of UPEC strain PA26B. UPEC PA26B was cultured in the
presence of prophage-inducing agents. After 12 h of growth,
bacterial cells were removed by filtration, and the supernatant
was tested for ADP-ribosyltransferase activity usingHsGi3N
as a substrate. In control reactions employing purified EcPltAB,
a robust ADP-ribosyltransferase response was observed using
20 nM pure toxin (Fig. 2c, 1st lane). Prior to commencing the
reaction, the supernatant of PA26B cells was seen to contain a
natively biotinylated 20-kDa protein, but this was readily dis-
tinguishable from our hostHsGi3N target (Fig. 2c, 2nd lane).
When HsGi3N was added to the filtered supernatant of
PA26B, we observed ADP-ribosylation of the substrate (Fig. 2c,
3rd lane) suggesting, but not conclusively proving, thatEcPltAB
is actively expressed.
The B subunit of the typhoid toxin impacts cell-signaling
pathways independent of its associated catalytic A subunits
(22). To determine whether the growth-arrest phenotype
induced by EcPltAB resulted from its enzymatic activity, inac-
tivating mutations were incorporated into the A subunit. A
highly conserved (Q/E)XE motif is present in many ADP-ribo-
syltransferases and is essential for activity (23) (residues
116QNE118 inEcPltA).Mutation of residueGlu-118 to an aspar-
tic acid residue resulted in a requirement for 1000-fold higher
concentrations of toxin to induce the same level of growth
arrest as wild-type EcPltAB toxin (Fig. 2d). Furthermore, a
Q116D,E118Ddoublemutant that retains awild-typeB subunit
showed no effect on growth and was indistinguishable from
control reactions even at 50 g/ml toxin (Fig. 2d and supple-
mental Fig. S2e), and as discussed later, this mutant displayed
no discernible enzymatic activity (Fig. 7c). EcPltAB thus
appears to be expressed by ExPEC, and its ADP-ribosyltrans-
ferase activity is cytotoxic to mammalian cells.
The presence of ATP, phosphate, and detergent assists with
activation of the PT S1 subunit by promoting dissociation from
its pseudopentamer and increasing its exposure to the local
microenvironment (24). ATP binds within the central pseu-
dopentameric pore of the pertussis toxin, destabilizing the
quaternary structure (25). We sought to determine whether
the activation requirements for the EcPltAB toxin were sim-
ilar. Our assay recapitulated the finding that reducing agents
activate PT and that this process is synergistically enhanced
by the presence of ATP (Fig. 3a, 1st to 5th lanes). Like PT, the
EcPltAB holotoxin is inactive when oxidized, and higher
concentrations of reducing agent result in increased cata-
lytic activity in vitro (Fig. 3a, 6th to 8th lanes). However, ATP
did not synergistically enhance this process (in Fig. 3a, 4th
lane is 95% more intense than 2nd lane, although the inten-
sities of the 7th and 9th lanes are within 1%). The ATP-
binding site of the PT pseudopentamer appears absent
within the homopentameric EcPltAB.We examined whether
the nature of the reducing agent affected EcPltAB activation
by repeating the ADP-ribosylation assays in the presence of
intracellular (2 mM) or serum (2 M) concentrations of glu-
tathione using different redox ratios. Reduced glutathione
alone was 20% more effective at inducing toxin activation
Figure 3. Activity assays for EcPltAB. a, ADP-ribosyltransferase assays similar to those used in Fig. 2 using biotinylated NAD as a substrate to modify
recombinantHsGi3NPT (left) and EcPltAB (right) holotoxinsweremonitored for activity for 5min at 37 °C in the presence of 10mM () or 100mM () TCEP
and with or without 10 mM ATP. b, EcPltAB activation in the presence of different ratios of reduced (GSH) or oxidized (GSSG) glutathione within the ADP-
ribosylation assay. c, 2D isoelectric focusing separation of different Gai isoforms isolated from bovine brain extract following treatment with EcPltAB or PT
indicate multiple Gai isoforms act as substrates.
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in vitro than an equivalent concentration of TCEP (Fig. 3c),
yet even small quantities of oxidized glutathione (GSSG)
drastically slowed activation. Thus, although some charac-
teristics are shared, the sequence divergence that exists
between pertussis toxin and pertussis-like toxins results in
differences in their respective activation mechanisms.
Protein substrates
PT targets the  subunits of human inhibitory trimeric
G-proteins by transferring the ADP-ribose moiety of NAD
onto a conserved cysteine four residues from their C termini.
PT-sensitive substrates primarily belong to the heterotrimeric
Gi/Go protein subfamily, which in humans includes the 40.5-
kDa proteins Gi1, Gi2, Gi3, and Gio, as well as the equiva-
lent subunit from transducin. The Salmonella ArtA pertussis-
like toxin modifies this same set of proteins (17), indicating
some degree of target conservation. As the HsGi3 was shown
to be an EcPltA substrate, we sought to test for activity against
the remaining trimeric Gi proteins enriched from brain lysate
using equal amounts of a commercial G-immunoprecipitated
source of trimeric inhibitor G-proteins. Mammalian inhibitory
Gi proteins possess similar molecular weights but have diver-
gent pI values (Gi2/Go (5.34), Gi3 (5.50), and Gi1 (5.7)),
allowing for their separation as three distinct bands on an iso-
electric focusing gel. PT-catalyzed ADP-ribosylation of brain
lysate (Fig. 3c, left panel) showed three distinguishable IEF
bands, roughly reproducing its substrate preference of G
i2
/
Go  Gi3  Gi1 (17). In contrast, when the same experi-
ment was performed using EcPltA, at least three subunits were
modified, with a slight relative preference for Gi3 over Gi2/
Go andGi1 (Fig. 3c, right panel).EcPlt thus represents a func-
tional AB5 toxin that retains some, but not all, characteristics of
the archetypical PT.
Protein substrate ADP-ribosylation site
Pertussis toxin specifically modifies a conserved cysteine
four amino acids from the C terminus of Gi/o subunits (26)
(Cys-351) and in doing so renders them unable to interact with
their cognate receptors (Fig. 4a). In ourADP-ribosyltransferase
assay, and as reported by others (27), C351S mutations within
the Gi/o proteins leave them resistant to PT modification but
surprisingly no modification by EcPltA (see Fig. 4b). To deter-
mine whether EcPltA targeted another cysteine residue, we
mutated each cysteine residue and repeated the experiment; all
suchHsGi3 mutants were simultaneously treated with PT as a
control. As shown in Fig. 4b, all other cysteine knock-out
mutants act equally well as substrates for either toxin. When
cholera toxin’s primary site of modification within stimulatory
Gs proteins is removed, lower affinity sites instead become
targeted (28). In case EcPltA targeted more than one cysteine,
we pretreated HsGi3 with iodoacetamide for 24 h and re-pu-
rified the protein prior to the assay (Fig. 4c). Alkylating all avail-
able cysteines renders HsGi3 resistant to PT modification as
expected, but it does not prevent the protein from being a sub-
strate for EcPltA, indicating an alternative chemical linkage.
The ADP-ribosylation products produced by EcPltA and PT
were not sensitive to 1 M hydroxylamine treatment suggesting
the modification is on residues other than Glu and Asp. How-
ever, lysinemethylation ofHsGi3 rendered it entirely resistant
to EcPltA modification (Fig. 4c). PT could still act on methy-
lated HsGi3 substrate but at a slightly reduced rate compared
with controls (Fig. 4c).
To identify the residue(s) withinHsGi3 modified by EcPltA,
the reaction product was subjected to MS-MS analysis. ADP-
ribosylation results in a 541-Da mass shift to precursor pep-
tides, and fragmentation of the pyrophosphate bond also liber-
ates a characteristic 348.1-Da adenine monophosphate during
product ion scans (supplemental Fig. S4).We obtained full pep-
tide coverage of HsGi3 and could not detect any evidence of
cysteine modification, instead ADP-ribosylated modifica-
tion sites were identified in HsGi3 C-terminal sequences:
331NVQFVFDAVTDVII-K(ADP-ribosylated)-NNLK349 and
346NN-(ADP-ribosylated)-LKECGLY354. Thus, EcPltA ADP-
ribosylates two residues (Lys-345 and Asn-347) at the C termi-
nus of HsGi3, sites distinct from PT modification of Cys-
351. We next constructed three mutants, HsGi3(K345A),
HsGi3(N346A), andHsGi3(N347A), and tested their suitabil-
ity as substrates for both toxins.HsGi3(K345A) was seen to be
resistant to ADP-ribosylation by EcPltA, yet it was readily
modified by the constitutively active PT S1 (Fig. 4d);
HsGi3(N346A) was readily ADP-ribosylated by either toxin
andHsGi3(N347A) by neither toxin (Fig. 4e). It is noteworthy
that mutation of either Lys-345 or Asn-347 to alanine also
reduced enzymatic activity against the other site, suggesting a
concerted mechanism of recognition. Together, these experi-
ments suggest that different pertussis-like toxins can target dis-
tinct but nearby residues within the C termini of Gi proteins.
Gi/o recruitment to GPCRs is disrupted by EcPltAB
Wenext examinedwhat effectEcPltABhad onGPCR-signal-
ing pathways in cells. The Relaxin family peptide 4 receptor
(RXFP4) is a GPCR that recruits Gi/o subunits upon binding
its ligand: insulin-like peptide 5 (INSL5); the induced nucleo-
tide exchange inhibits forskolin-stimulated cAMP production
and promotes ERKphosphorylation (29), a response that can be
abolished through PT pretreatment. Gi/o proteins with a
C351I mutation (mGoA, mGoB, mGi1, mGi2, or mGi3)
are PT-insensitive and can be used to rescue the PT-abolished
INSL5-stimulated ERK1/2 response to determine which Gi/o
subunits are recruited to RXFP4. We first confirmed that PT
could completely abrogate the INSL5-stimulated ERK1/2
response within Chinese hamster ovary (CHO)-RXFP4 cells
transfected with the pcDNA3 vector control (Fig. 5a); an iden-
tical result was obtained with EcPltAB pretreatment (Fig. 5a).
Next, we demonstrated that ERK1/2 responses were partially
restored in PT-treated cells transfected with mGoA, mGoB,
mGi2, and to a smaller extent with mGi3 but negligibly with
Gi1 (Fig. 5, b–f). GPCR RXFP4 can thus recruit all isoforms of
Gi/o, although it does so in a preferential manner, predomi-
nantly recruitingGoAGoBGi2Gi3Gi1. None of
the PT-insensitive Gi/o mutants tested were able to restore
INSL5-stimulated ERK1/2 responses in cells treated with
EcPltAB (Fig. 5, b–f), underlining thatwithin cells the residue(s)
onGi/o targeted by EcPltAB differ from the canonical Cys-351
ADP-ribosylated by PT and that once modified the GPCR sig-
naling is disrupted.
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As Gi/o subunits carrying the PT-resistant C351I mutant
remain sensitive to EcPltAB treatment, we next sought to iden-
tify alternative EcPlt-resistant mutations. To do so we moni-
tored the cAMPconcentration in cells responding to the adeny-
lyl cyclase activator forskolin (supplemental Fig. S5a). This
stimulatory response can be counteracted by inhibitory trim-
eric G-proteins coupled to INSL5-induced RXFP4 signaling,
which acts to restore cAMP levels to a near basal state (supple-
mental Fig. S5a). The RXFP4-transduced inhibitory signal can
be abrogated by either toxin (supplemental Fig. S5a), and
reconstituting C351I Gi/o subunits allows partial recovery of
the inhibitory signal in the presence of PT (supplemental Fig.
S5, b–f) but not EcPltAB. In an attempt to achieve an equivalent
response for the enterobacterial toxin, wemutated its two iden-
tified ADP-ribosylation sites within HsGi3 to alanine (N347A
and K345A) and repeated the experiment (supplemental Fig.
S5, g and h). NeitherHsGi3(N347A) norHsGi3(K345A) facil-
itated the recovery of PT-treated cells. In contrast, EcPltAB
treatment of cells transfected withHsGi3(N347A) displayed a
26  5% difference in the cAMP response in the presence of
Figure4. Proposedmodel of thepertussis-like toxins transfer target.a, structure of opsin in complexwith theC terminusof transducin (Scheerer et al. (38),
Protein Data Bank code 3DQD); their K345L mutant was reverted to lysine for this figure. Gi3 is shown in teal; the position of the C terminus and ADP-
ribosylated residues discussed in text are shown. The plasma membrane and GPCR (green) are at the top. b, ADP-ribosyltransferase assays using EcPltA or
pertussis toxin inwhich potential acceptor cysteineswithin Gi3Nweremutated to serine; or c, following iodoacetamide and lysinemethylation; d, mutation
of Lys-345; or e, Asn-346 and Asn-347 to alanine.
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INSL5/forskolin or forskolin alone (supplemental Fig. S5g),
consistent with the N347A mutant providing a degree of pro-
tection for EcPltAB but not for PT. In the same experiment,
HsGi3(K345A) did not obviously allow recovery of INSL5-me-
diated signaling (Fig. 7h).
Structure of the secreted EcPltAB holotoxin
To understand the secreted ExPEC toxins in more detail,
we determined the 2.4 Å crystal structure of the EcPltAB
holotoxin (see supplemental Methods and Table 1 for
details). This heterohexameric complex resembles a blunted
pyramid in which the EcPltA subunit sits atop a pentameric
B subunit base, thereby adopting an overall quaternary
structure of the AB5 family (Fig. 6a). In the secreted oxidized
state, the enzymatic A subunit contains a single intramolec-
ular disulfide bond between the two conserved cysteines
(Cys-41 and Cys-192, Fig. 6b); each of the five EcPltB sub-
units contains a further two intramolecular disulfides.
EcPltA shares 52% sequence identity to the typhoid toxin’s A
subunit (30) and 31% identity to the S1 subunit of pertussis
toxin (9), its two closest known structural homologs (root
mean squared deviation of 1.1 Å over 207 of 224 C; and 2.0
Å over 186 C, respectively PDBeFOLD). In all three holo-
toxins, the respective orientation of the A subunit atop the B
pentamer is similar, with the C backbone structure of the
EcPlt holotoxin and the lower AB5 section of the typhoid
toxin overlaying over most of their length. The conserved
intramolecular disulfide of pertussis group toxins holds their
inhibitory C-terminal residues inside their nucleotide-bind-
Figure 5. EcPltABdisruptsG-protein-coupled signaling. RXFP4 recruits Gi/o subunits upon ligand activation. PT pretreatment abolishes INSL5-stimulated
ERK1/2 phosphorylation, and this is rescued to differing degrees by transfection of individual PT-insensitiveGi/omutants. a,Chinese hamster ovary-RXFP4 cells
were transiently transfected with pcDNA3 vector control, or b–f, Gi/o constructs carrying the C351I mutation (mGoA, mGoB, mGi1, mGi2, or mGi3).
Blockade of the response to PT but not EcPltAB pretreatment was rescued by transfection of the mutant G-proteins. Cells were stimulated with mouse INSL5
alone (0.1 to 100 nM) or after pretreatment with PT (100 ng/ml) or EcPltAB (100 ng/ml). Data points represent mean S.E. of three independent experiments
and are expressed as the % response of the positive control (10% v/v FBS). Veh, vehicle.
Table 1
Data collection and refinement statistics
EcPltAB EcPltA1
Data collection
Redox state Oxidized Reduced
Space group P65 P1
Cell dimensions
a, b, c (Å) 160.9, 160.9, 62.6 44.5, 55.7, 73.1
, ,  (°) 90.0, 90.0, 120.0 90.1, 104.1, 96.2
Resolution (Å) 49.4–2.35 (2.48–2.35) 70.8–1.80 (1.90–1.80)
Rpima 4.1 (35.6) 6.6 (30)
I/1 12.1 (2.1) 7.7 (2.6)
Completeness (%) 99.9 (99.7) 88.5 (87.7)
Total no. of observations 326,219 (45274) 91,849 (12898)
No. of unique observations 38,825 (5619) 55,479 (8027)
Multiplicity 8.4 (8.1) 1.7 (1.6)
Refinement statistics
Rfactor b (%) 19.2 (30.0) 18.1 (26.1)
Rfreec (%) 25.5 (34.3) 22.7 (31.6)
No. of atoms
Protein 6380 5591
Ligand 1 (PO4) 176 (4 NAD, 2Na)
Water 64 598
Ramachandran plot (%)
Most favored 94.0 97.5
Allowed region 6.0 2.5
Outlier 0.0 0.0
B-factors (Å2)
Protein 68.1 16.2
Root mean square deviation
bonds (Å)
0.011 0.010
Root mean square deviation
angles (°)
1.37 1.18
a Rp.i.m hkl(1/(N	 1))1/2 iIhkl, i	 
Ihkl/hkl
Ihkl.
b Rfactor (Fo	 Fc)/(Fo) for all data except as indicated in Footnote c.
c 5% of data was used for the Rfree calculation.
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ing sites (Fig. 6b), preventing catalytic activity prior to entry
into the reducing environment of the host cytoplasm.
Structure of the cytoplasmic NAD-bound EcPltA
To determine what structural changes occur following
release of the C-terminal redox switch, we determined a 1.8-Å
resolution structure of the constitutively active catalytic EcPltA
subunit (residues 5–181) purified under reducing conditions
(Table 1). As ART enzymes display off-target NAD-glycohy-
drolase activity in the absence of substrate, we utilized the cat-
alytically inactive mutant (Q116D,E118D) to slow this reaction
and permit stable co-complex formation with the NAD sub-
strate (30). These crystals diffracted in space group P1with four
complexes of NAD–EcPltAcat within the asymmetric unit
allowing independent models of the ART domain to be com-
pared. The enzymatic core of the ART fold consists of 150
amino acids and has a U-shape with a concave cleft creating the
NAD-binding site (Fig. 6c). The two -sheets of EcPltA are on
either side of this nucleotide-binding cleft: on one side is the
-sheetwith strands s1, s3, s6, and s7 sandwiched betweenhelix
3 and helix 1, and on the other side is the fold’s smaller s2, s5,
and s4 -sheet along with its h2, h4, and h5 helices. Unbiased
omit maps showed NAD to be bound inside the U-shaped
ART domain with two distinct binding modes observed, one
extended and the other semi-extended (Fig. 7) (31). The
extended conformation (supplemental Fig. S6a) dominates in
theA, B, andCprotomers and the semi-extended conformation
inD (supplemental Fig. S6b). Both bound forms ofNAD adopt
highly folded nicotinamide mononucleotide (NMN) sections,
whereas the adenine base transits between alternative aromatic
stacking interactions. The common factor within the two dis-
tinct nucleotide conformations is the folded NMN group, and
forcing the nucleotide to adopt this form is proposed to be an
integral part of catalysis (32). The residues stabilizing the com-
pact NMN are contributed from both sides of the binding cleft.
Strand s1 provides a conserved phosphate-binding nucleo-
Figure 6. Activation mechanisms of EcPlt and cholera toxin. a, schematic representation of the EcPltAB holotoxin in which -helices are colored marine,
-strands wheat, and loop regions green. The C-terminal A2 domain is highlighted in pink showing its interaction with the B subunits of the glycan-binding
pentamer (gray). b, schematic representation highlighting the holotoxin’s EcPltA subunit. The conserved redox-sensing disulfide is labeled, and the rough
position of the B-pentamer is shown as a partially transparent structure. Predicted potential proteolytic sites are shownwith partially transparent scissors, and
the C terminus is marked Ct. c, reduced active NAD co-complex with all secondary structural elements labeled. The enzymatically cleavedN-glycosidic bond
cleaved during the course of the reaction is highlighted.
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philic amino acid (Arg-9) also found in PT, although the amide
group of the nicotinamidemoiety forms hydrogen bonds to the
peptide backbone (Fig. 7a). On the other side of the cleft, resi-
dues within a semi-conserved “STS” motif within the s2 strand
position the scissile bond for catalysis by clasping the nicotinic
ring ofNAD (actual residues 52ATT54, supplemental Fig. S6c).
The inactivating E118D mutation of the catalytically essential
glutamate shifts the negatively charged carboxyl away from the
nucleotide (Fig. 7, a and b); if the Glu-118 rotamer observed in
the wild-type holotoxin was to be maintained following reduc-
tion, its carboxyl group would be positioned within hydrogen-
bonding distance of the N-ribose’s 2-hydroxyl (Fig. 7e). This
interaction is highly conserved within ART enzymes and is
thought to promote nicotinamide scission by stabilizing the
formation of an oxocarbenium ion intermediate (33). The
movement of the carboxyl group caused by theE118Dmutation
helps explain why this otherwise relatively conservative substi-
tution is inactivating in the ART enzymes (Fig. 7c).
In the extended NAD conformation, the adenine base
interleaves between the guanidinium group of Arg-13 and the
indole ring ofHis-26. A similar interleaved interaction is seen in
the NAD-bound cholera toxin structure (15). In contrast, the
semi-extended NAD conformation has the adenine base
stacked atop Tyr-67 (Fig. 7b). The Y67A mutation was seen to
abrogate catalytic activity in the ADP-ribosyltransferase assays
usingHsGi3 as substrate (Fig. 7c), but25%wild-type activity
is retained by Y67F mutants suggesting it is the aromatic base-
stacking role that is itsmore vital feature (Fig. 7c).Moreover, an
S70W mutation, which would disrupt the adenosine-binding
site of the semi-extended but not the extended conformation,
also displayed minimal ADP-ribosyltransferase activity in vitro
(Fig. 7, b and c) suggesting this conformation may play a role
during catalysis.
Several EcPltA residues located at the intersubunit interface
of the holotoxin become solvent-exposed following subunit
dissociation; this includes Ile-111 on h5 and Ile-58 and Ser-56
on h3 (gray labels in Fig. 7b). To determine whether any such
residues are also involved in protein interactionswith the trans-
fer target, they were mutated to large bulky residues to disrupt
potential recognition interfaces. All mutations on the exterior
face of h3 had no effect (Fig. 7c), whereas equivalent mutations
on h5 (I111Y) were inactivating. This h5 helix is N-terminal to
the catalytic (E/Q)XEmotif, a region of the ART domain that in
cholera and C3-like toxins corresponds to a conserved flexible
loop between strands s4 and s5 known to be necessary for sub-
strate recognition (34).
Redox-induced structural changes
Wecompared the inactive oxidized and activeNAD-bound
states of EcPltA (Fig. 7e; supplemental movie). This shows that
the activation mechanism of pertussis-like toxins is fundamen-
tally different from the loop-refolding mechanism of cholera
toxin (15). The conserved intramolecular disulfide within the
EcPltA-oxidized state (Cys-41–Cys-192) is located inside the
NAD-binding cleft directly above the catalytic glutamate
(Glu-118), Cys-192 being the C-terminal residue of the short
inhibitory A2 helix. In the holotoxin, the binding pocket for the
nicotinamide ring is filled by Phe-193 from hA2 (Fig. 7d); sub-
sequent A2 backbone residues then rise to thread through the
cleft with Arg-199 and Arg-200 occupying the same site as the
adenosine ring in the extended conformation (pink loop in Fig.
7d). The A2 loop subsequently doubles back on itself before
entering the pentamer pore; during this descent, it blocks the
adenosine-binding site near helix 3 for the semi-extended con-
formation (Fig. 7b). The nucleotide-binding site of EcPltA is
made from dynamic regions of the protein that move following
release of the inhibitory C-terminal residues as well as regions
that remain stationary. A static floor capable of accommodat-
ing either NAD or the A2 peptide includes the adenine base-
interleaving residues Arg-13 and His-26 (Fig. 7a), the phos-
phate-binding nucleophile Arg-9, and the nicotinamide “STS”
clasp equivalent residues. In contrast, structural movements
are required to form the side walls of the NAD-binding site.
This is necessary as the occluding C-terminal helix is more
bulky than the substrate nucleotide.
After the redox-sensing disulfide is reduced, Cys-41 and the
remainder of the active-site loop undergo an2.5-Å rigid-body
inward movement toward the adenosine ribose and phosphate
(Fig. 7e). This loopmovement carries the h2 helix with it until it
abuts the 3-hydroxyl of the N-ribose, and in doing so the cat-
alytic residue His-35 (35) is shifted toward the scissileN-glyco-
sidic bond (Fig. 7, a and e) where it may interact with Glu-118.
Following NAD binding, helix 3 pivots about its N terminus
resulting in a maximal displacement from the oxidized form of
8.2 Å (Fig. 7e). This movement allows the side chains of
Tyr-67 and Ile-63 to move in and neighbor the nicotinamide
ring. These NAD-binding associated movements are likely to
be conserved features of activation within typhoid toxin and
pertussis toxin.
Discussion
We provide the structural details of the E. coli pertussis-like
toxin in its intracellular reduced form, detailing different sub-
strate-binding modes and the redox-induced structural
changes that occur during activation. In the oxidized state, the
disulfide-linked C terminus of the A subunit inactivates the
protein by occluding the NAD-binding site (Fig. 6), a mecha-
nism clearly conserved within pertussis toxin as suggested by
modeling studies (36). Loss of the inhibitory A2 domain from
within the nucleotide-binding cleft allows significant lobe clo-
sure and reorganization of residues about NAD particularly
within helices h2, h3, and the active-site loop. This contrasts
with the activation mechanism of the cholera toxin whose A2
domain is largely external to the catalytic cleft and requires no
Figure 7. NAD-binding site of EcPltA. a, structure of EcPltAwith NAD bound in the extended conformation; residues investigated for their role in binding
and catalysis are labeled, as are the nicotinamide STS-clasp equivalent residues 52ATT54. b, structure of the semi-extended NAD conformation, approximate
positionof occluding residuemutants are shown ingray. c,ADP-ribosyltransferase assay response relative towild-typeprotein for variouspointmutantswithin
theNAD-binding site. Error bars are the S.D. of three independent replicates.d,depictionofwhere the residues important forNADbinding are located in the
oxidized holotoxin and their interactions with the occluding A2 helix (pink). e, overlay highlighting the structural changes occurring during activation/NAD
binding. The semi-extended NAD-bound structure (blue helices and orange loop) is compared with the oxidized holotoxin (cyan helices and yellow loop).
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lobe movements upon activation, but it involves significant
loop restructuring (30). Our high-resolution co-crystal struc-
ture details NAD binding in two distinct conformations: the
dominant extended conformation is similar to that observed in
nucleotide-soaked CT crystals (30), and a second lower-occu-
pancy semi-extended conformation also exists and may play a
role during catalysis as C-terminal h3 mutations predicted to
disrupt the base-stacked adenine abrogate activity.
The residues within h2 are relatively well-conserved, sug-
gesting the redox-inducedmovement of this structural element
and the restructuring of the preceding active-site loop are a
conserved features of pertussis-like proteins. In contrast, heli-
ces h3 and h5 show more significant structural divergence
between the pertussis and the enterobacterial holotoxins, with
these regions more likely involved in binding to the transfer
target. GPCR binding is disrupted by pertussis toxin through
modification of the Gi residue Cys-351, and the toxin is highly
specific and unable to modify mutants lacking this residue (Fig.
6). The extent to which pertussis-like toxins are conserved
could have correlatedwith conservation of target chemistry, yet
we show EcPlt does not modify cysteine residues within Gi
proteins but instead a lysine and asparagine several residues
away. Moreover, our cAMP experiments confirmed that
EcPltAB enters cells and inhibits the action of Gi proteins via a
residue other than Cys-351 (Fig. 4). This is not unprecedented;
human poly(ADP-ribose) polymerase 1 initiates polymer for-
mation on C-terminal chromatin lysines (37), but ADP-ribosy-
lation at such sites has not previously been described within
bacterial toxins nor in humanG subunits.Whywould this site
be targeted? GPCR:G-protein coupling occurs when the pre-
dominantly helical C terminus of the G subunit inserts into a
pocket built from the cytoplasmic facing ends of the receptor
TM helices. The co-complex structure of opsin in complex
with theC terminus of transducin (38) shows that Cys-351 pen-
etrates deep into the binding pocket, highlightingwhy pertussis
toxin’s modification would be incompatible with receptor cou-
pling. As the C terminus of receptor-bound G subunits are
predominantly helical, Asn-347 lies a turn beneath Cys-351
interacting with the same transmembrane helix (TM3). Lys-
345 is on the opposing side of the G-protein’s C terminus inter-
facingwithTM6. Thus, bothAsn-347 and Lys-345 reside closer
to the cytoplasmic “mouth” of the receptor’s binding pocket
than Cys-351 when coupled to their cognate GPCRs.
EcPltA-catalyzed ADP-ribosylation may thus block receptor
recruitment of inhibitory heterotrimeric G-proteins using a
related but distinct mechanism to that used by pertussis toxin.
Our attempts to create an EcPlt-resistant Gi3 subunit were
partially successful (supplemental Fig. S5) and could be inter-
preted as indicating that the Asn-347 modification may domi-
nate over the Lys-345 site in vivo. In vitro, both Lys-345 and
Asn-347 were required for EcPltA to modify HsGi3, so both
residues may be involved in toxin:G-protein binding. Peptides
consisting of the 10–20 C-terminal residues of HsGi3 can act
as minimal pertussis toxin substrate inhibitors (39) suggesting
the entire protein is not necessarily required for recognition.
Our work might imply that EcPlt has shifted its respective rec-
ognition motif within Gi proteins several residues down-
stream from that of PT with Asn-347 playing distinct roles in
both EcPlt and PT toxins recognition interfaces; we note that
Asn-347 appears to be more essential for the action of EcPlt as
its mutation did not provide sufficient protection to reconsti-
tute signaling in the presence of PT. Further work will be
required to validate our reconstitution experiments; mutants
that disrupt the toxin–G-protein interface may also influence
GPCR binding and/or GTPase activity.
Finally, pertussis toxin has become a valuable tool for dissect-
ingGPCRpathways, and the identification of an expanded tool-
set of pertussis-like proteinswith varied inhibitorymechanisms
may permit additional experiments to be performed. Given the
proven utility of PT in this role, it may be beneficial to further
characterize the behavior of other pertussis-like toxins in
reconstituted systems to fully understand how this toolset
functions.
Experimental procedures
Materials
All chemicals were purchased from Sigma unless otherwise
stated. Mouse INSL5 was synthesized and purified at The Flo-
rey Institute of Neuroscience and Mental Health (Melbourne,
Australia) by Dr. Akhter Hossain (40). FBS, DMEM Ham’s/F-
12, Lipofectamine 2000, and PT were all from Life Technolo-
gies, Inc. AlphaScreen SureFire ERK1/2 phosphorylation kits,
acceptor beads, and donor beads were all from PerkinElmer
Life Sciences.
Bioinformatic analysis and bacterial strains
E. coli strains containing AB5-type toxin-like genes were
identified from an E. coli dataset (EcoDS) comprising 1700
genome sequenced strains deposited in the NCBI database up
to January 2014 (56), using a querying dataset based on charac-
terizedAB5 toxins (Art (16), Shiga (41), subtilase (42), and chol-
era (43) toxins). Sequence comparisons were performed using
the FASTA36 package (44); ORFs with an amino acid sequence
identity 75% of the toxin subunits were extracted from
the public dataset. A neighbor-joining tree was generated using
the concatenated AB toxin subunits with ClustalW (45). The
phylogenetic group was determined using an in silico triplex
scheme (46, 47), and MLST analysis was performed according
to a seven-gene scheme described previously (48). UPEC strain
PA26B was isolated from a patient presenting with a urinary
tract infection at the Princess Alexandra Hospital (Brisbane,
Australia) (54).
Toxin expression
Toxin expression was induced by stressing PA26B cells and a
control K12 laboratory strain, and overnight cultures grown at
37 °C were diluted 1:40 into 40 ml of LB broth without antibi-
otics and grown for 4 h at 37 °C before addition of mitomycin C
or 10 mMH2O2. After 24 h of growth, all proteins secreted into
the media were harvested and clarified by passing through a
0.2-m filter. 10 nM bovine catalase was added to the superna-
tant of cells stressed by H2O2.
Cytotoxicity assay
Kidney epithelial cells from the African green monkey (Vero
cells) or human embryonic kidney (HEK293T) were expanded
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to 40–50% confluency in 10-cm2 dishes covered with 2 ml of
Dulbecco’s modified Eagle’s medium supplemented with 10%
(v/v) fetal calf serum. Cytotoxicity assays were performed by
adding recombinant EcPltAB holotoxins at 50 g/ml to 500
pg/ml. Cells were left for 18 h and then stained with crystal
violet and imaged. The surface area covered by the cells was
determined by the number of blue pixels within each image
normalized against buffer controls.
Cloning
A co-expression vector for the EcPltAB toxin was created as
in Ng et al. (12). Briefly, both the full-length EcPltA and EcPltB
genes were chemically synthesized (GenScript), with the addi-
tion of restriction sites NdeI and XmaI and XbaI and XhoI
flanking the EcPltA and EcPltB open reading frames, respec-
tively. The EcPltA gene containing its native signal sequence
was cloned directly into pBAD18. EcpltB was subcloned into
pET-23 (Novagen) via XbaI and XhoI sites, resulting in a pro-
tein with a C-terminal poly-His tag and N-terminal PelB signal
sequence; this construct was used for the expression of unligan-
ded EcPltB pentamer. To produce the co-expression vector for
EcPltAB, the ribosome-binding site and EcPltB was excised
from pET-23 using the XbaI and HindIII restriction sites prior
to being cloned downstream of EcPltAwithin the pBAD vector.
The catalytic domain of the pertussis toxins S1 subunit,
EcPltA, and human HsGi3 proteins were cloned into a pET28
expression vector fused to a hexahistidine tag through a human
rhinovirus 3C cleavage site. The constitutively active EcPltA
construct encompassed residues 5–181. TheHsGi3 constructs
encompassed residues 034-354 or 005-354. Mutants used in
enzymatic assays were created by oligonucleotide-directed
mutagenesis followed by DpnI digestion of the parental vector,
with all resulting constructs confirmed by sequencing.
Protein expression and purification
For protein expression, EcPltAB was transformed into E. coli
BL21(DE3) cells and then grown in LB at 37 °C containing 100
g/ml ampicillin to A600  0.6 followed by a 4-h induction at
37 °C with 0.2% L-arabinose. Cell culture pellet was collected
and resuspended in HEPES-buffered saline (HBS) (20 mM
HEPES, pH 7.0, 150 mM NaCl) and stored at 	20 °C. The cell
pellet was thawed, lysed, and centrifuged with the supernatant
collected and loaded onto 5 ml of nickel-Sepharose beads (GE
Healthcare), equilibrated in 50 mM HEPES, pH 7.0, 250 mM
NaCl, 60 mM imidazole. Unbound material was removed by
washing with the same buffer. Protein was eluted with 1 M im-
idazole buffer (20 mM HEPES, pH 7.0, 250 mM NaCl, 1 M imid-
azole), with 5-ml fractions collected. Fractions containing
EcPltAB were pooled, buffer-exchanged into HBS, and loaded
on a Superdex S200 16/60 gel filtration column (GEHealthcare)
where it eluted with a molecular mass consistent with that of a
heterohexamer (100 kDa).
Protein expression of EcPltA constructs were performed in
BL21 (DE3) E. coli cells that were grown at 37 °C in LBmedium
supplemented with 30 g/ml kanamycin. After reaching an
A600 nm of 0.6–0.8, the temperature was dropped to 18 °C, and
the cells were induced for 18 h with 0.2 mM isopropyl -D-1-
thiogalactopyranoside. Cells were harvested and resuspended
in HBS with 20 mM imidazole and 1 mM TCEP, then lysed by
adding 1 mg/ml lysozyme and DNase, and then sonicated.
Cleared lysate was applied to a Ni-NTA affinity column and
washed extensively before eluting in 20mMHEPES, pH 7.0, 250
mM NaCl, 400 mM imidazole, 1 mM TCEP. The protein’s hexa-
histidine tag was cleaved by incubating the eluted protein with
0.1 mg/ml GST-fused HRV 3C overnight at 4 °C. The HRV 3C
protease was removed by passing over 0.1 ml of GSH-agarose
resin with the flow-through subsequently purified by gel filtra-
tion on a Superdex S75 16/60 (GE Healthcare). The constructs
eluted as a single peak corresponding to monomeric EcPltA.
The pertussis toxin’s catalytic S1 domain was purified using a
similar manner.
Expression of the different HsGi3 constructs was identical
to that of EcPltA except they required 0.01% (v/v) Triton X-100
duringHRV3Ccleavage, and the proteinwas buffer-exchanged
into 20mMHEPES, 50mMNaCl, 1mMTCEP to allowHiTrapQ
purification prior to gel filtration. When HsGi3 mutants were
being purified for enzymatic assays, chromatographic systems
and columns were purged with two intervening dummy runs:
one of 0.5 M NaOH followed by 1 M HEPES, pH 7.0. When
required, HsGi3N was methylated using a reductive alkyla-
tion kit (Hampton Research HR2-434) or carbamidomethy-
lated with iodoacetamide (Pierce 90034) according to the man-
ufacturer’s instructions prior to the ion-exchange column
during purification.
Enzymatic assay
Activity assays were performed using 6-Biotin-17-NAD
(BPS Biosciences 80610) as a substrate for the modification of
different G-protein substrates. The resulting biotin adducts
were visualized using streptactin-conjugated horseradish per-
oxidase (Bio-Rad 161-0381). Briefly each reaction mix con-
tained 1 M protein substrate, which consisted of recombi-
nant HsGi3, purified trimeric bovine brain G-proteins (EMD
Millipore 371739), or whole Vero cell lysate. Standard assay
conditions consisted of1 MG-protein in 20 mMHEPES, pH
7.0, 140mMNaCl, 5mMTCEP, and 10Mbiotin-NAD, which
was incubated for 5 min at 37 °C with 20 nM toxin. Holotoxin
assays were performed with up to 100 mM TCEP to induce
activation and consisted of PT purified from Bordetella lysate
(Sigma P7208) or recombinant EcPltAB. Reactions were
stopped by adding SDS-loading buffer and heating at 100 °C for
5min before analysis by SDS-PAGE. Analysis by 2D gel electro-
phoresis was done by the Proteomics Facility, Monash Univer-
sity; samples were separated in the 1st dimension over broad
PIG pH strip (pH 3–10) before separation in the second dimen-
sion by SDS-PAGE (gradient of 9–16% acrylamide). 1D and 2D
gels were processed for analysis byWestern blot; proteins were
transferred to a membrane prior to being visualized using
streptactin-HRP and Pierce chemiluminescence substrate.
Assays performed with recombinantly produced G-proteins
were subsequently stained by Coomassie to ensure equal load-
ing. All assays were repeated three times to ensure reproduc-
ibility. Densitometrywas performed using an EpsonV700 scan-
ner and data quantification via ImageQuant.
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Crystallization data collection and structure determination
The EcPltAB holotoxin crystals were obtained by setting up
1:1 ratio hanging drop experiments with 16mg/ml protein over
a reservoir of 0.2 M MgCl2, 0.1 M Tris-HCl, pH 8.5, 15% (w/v)
polyethylene glycol 3350 at 293 K; crystals took 2–3 weeks to
grew and were then harvested by flash-freezing in liquid nitro-
gen after soaking in a cryoprotectant solution containing an
additional 25% (v/v) glycerol prior to data collection. EcPltAB
crystals diffracted to 2.35Å in space group P65with one hetero-
hexamer in the asymmetric unit, and initial maps were gener-
ated using the lower AB5 section of the typhoid toxin (7) as a
molecular replacement model (49) in the program Phaser (50).
The resulting electron density allowed rounds of manual build-
ing and refinement using the programs COOT (51) and PHE-
NIX (49). Because of the moderate resolution, NCS constraints
weremaintained throughout refinement, as releasing restraints
did not result in significant improvements in Rfree. The final
model encompasses residues 1–114 across all five protomer B
subunits and residues 4–226 in the A subunit.
The reduced EcPltA(Q116D,E118D) mutant at 6–8 mg/ml
was complexed with 20mMNAD for 30min before setting up
in hanging drop crystallization experiments using a 1:1 ratio at
277 K. Clusters of plate-like crystals grew within 2–3 days over
reservoirs containing 4–7% (v/v) polyethylene glycol, 0.1 M
Tris, pH 8.5, and 150mM Li2SO4. Crystals clusters were broken
into single pieces prior to freezing in a reservoir complemented
with 25% (v/v) glycerol and flash-frozen in liquid nitrogen, sub-
sequently diffracting in a monoclinic space group to 1.8 Å with
four molecules in the asymmetric unit. A molecular replace-
ment solution was obtained using a trimmed version of the
holotoxin’s A1 subunit as a model with four molecules found
within the asymmetric unit. In protomers A–D, clear electron
density was observed for residues 4–174, and there were few
differences in the C backbone structure among protomers
except for a shift in protomer D within the loop C-terminal to
h3. The final model contains four NADmolecules and all but
the C-terminal residue of the construct.
Data completeness for the EcPltA in space group P1 was a
little lower than ideal.WhenPTorEcEPlt dissociates from their
B subunits, theymimic unfolded proteins to translocate toward
the cytosol. In such structures h5 is highly flexible so crystals
often grew as oddly shaped clusters that needed to be frag-
mented. In the four molecules in the asymmetric unit, the h5
loop adopts different forms; moreover, such conformations
varied when data were collected at different points in the crys-
tal. This structural complexity caused issues for merging of
datasets, and crystals showed some radiation damage after
150–200°, and the dataset was collected from multiple points
on a single crystal.
Glycan array analysis
Purified EcPltAB protein at 1 or 100 g/ml was applied to a
PA_v51 glycan microarray at the Consortium of Functional
Glycomics Protein–Glycan Interaction Core at Emory Univer-
sity, and binding was detected using Alexa488-conjugated anti-
hexahistidine antibody. The data are reported as average rela-
tive fluorescence units of four of six replicates (after removal of
the highest and lowest values) for each glycan represented on
the array.
Mass spectrometry analysis
HsGi3 at 2 mg/ml was treated for 1 h with a 100:1 molar
ratio of EcPltA in 20 mMHEPES, 150 mMNaCl, 2.5 mMNAD,
0.5 mM TCEP, pH 7.5. After the reaction, the protein was
diluted into 20 mM HEPES, 50 mM NaCl and then bound to a
HiTrap Q column and eluted under a 20-ml gradient to 1 M
NaCl to remove unreacted NAD. The reaction product was
diluted into 100mM (NH4)HCO3 and heated to 95 °C for 5min;
after cooling to room temperature, the sample was divided in
two with fresh chloroacetamide added to one fraction at a final
concentration of 5 mM for 30 min. Trypsin was then added at a
1:50 ratio with the digestion allowed to proceed for 18 h at
37 °C, and the digestion was finally quenched with formic acid
at a final concentration of 0.25% (v/v). The resulting peptides
were analyzed by LC-MS/MS using the QExactive mass spec-
trometer (Thermo Fisher Scientific, Bremen, Germany) cou-
pled on linewith anRSLCnano-HPLC (Ultimate 3000, Thermo
Fisher Scientific) (52). MS/MS data analysis was done with
MaxQuant software (build 1.5.2.8); MS data were analyzed
using MaxQuant (53) searched against the human and E. coli
K12 strain protein sequences taken from UniprotKB (March,
2015). ADP-ribosylation was defined as modification of a mass
of 541.0611088 Da on with diagnostic peaks of 438.03699 (m8),
348.07036 (m6), 250.09346 (m3), and 136.06177 (m1) and the
corresponding natural loss peaks. The search parameters
include enzyme specificity of trypsin with three missed cleav-
ages. Search parameters also allowed for cysteine carbamido-
methylation, methionine oxidation, or ADP-ribosylation on
cysteine, lysine, arginine, glutamate, aspartate, and asparagine.
All other search parameters were set to the default settings.
Cell culture and transient transfection
CHO cells stably expressing RXFP4 (CHO-RXFP4) were a
gift from Associate Professor Ross Bathgate (Florey Institute of
Neuroscience andMental Health, Melbourne, Australia). Cells
were grown and maintained in 175-cm2 flasks in DMEM/F-12
medium supplemented with 5% (v/v) fetal bovine serum (FBS)
at 37 °C in humidified air containing 5%CO2. cDNA constructs
for G-protein  subunits (GoA, GoB, Gi1, Gi2, or Gi3) con-
taining the C351I mutation were from the cDNA Resource
Center (Bloomsberg, PA). HsGi3 containing K345A and
N347Amutationswere generated via site-directedmutagenesis
using wild-type HsGi3 pcDNA3 vector as template. HsGi/o
constructs carrying the mutations were transiently transfected
into CHO-RXFP4 cells grown on 6-well plates using Lipo-
fectamine 2000 as per the manufacturer’s protocol.
ERK1/2 phosphorylation
18 h after transfection, CHO-RXFP4 cells were trypsinized
and seeded onto 96-well plates at a density of50,000 cells per
well and incubated for 6–8 h in complete media to allow cell
adhesion. Cells were then incubated with PT, EcPltAB, or con-
trol (serum-free DMEM/F-12) for 18 h before stimulation with
mouse INSL5 (0.1 to 100 nM) for 5 min and then lysed. Phos-
phorylation of ERK1/2 (Thr-202/Tyr-204) was detected using
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the AlphaScreen SureFire kit. In brief, 4 l of cell lysates was
added to a white 384-well microplate (ProxiPlate; PerkinElmer
Life Sciences) containing 5 l of acceptor bead mix (40 parts
reaction buffer/10 parts activation buffer/1 part protein A
acceptor beads) and incubated for 2 h at 23 °C. Then, 2 l of
donor bead mix (20 parts dilution buffer/1 part streptavidin-
coated donor beads) was added and incubated for 2 h at 23 °C.
All additions and incubations were carried out under low light
conditions to avoid photobleaching. Fluorescence readings
weremadeusing the Envisionmultilabel plate reader (PerkinEl-
mer Life Sciences; excitation  680 nm; emission  520–620
nm). ERK1/2 phosphorylation is expressed as a percentage
response to 10% (v/v) FBS (positive control).
Inhibition of cAMP accumulation
18 h after transfection, CHO-RXFP4 cells were trypsinized
and seeded onto 96-well plates at a density of50,000 cells per
well and incubated for 6–8 h in complete media to allow cell
adhesion. Cells were then incubated with PT, EcPltAB, or con-
trol (serum-free DMEM/F-12 medium) for 18 h. On the day of
experiment, we changed the medium to Hanks’ balanced salt
solution supplemented with 500 M isobutylmethylxanthine, 5
mM HEPES, and 0.1% (w/v) BSA and equilibrated for 1 h at
37 °C. Cells were treated with INSL5 (100 nM) for 15 min, fol-
lowed by 30 min of forskolin stimulation and then lysed with
100% ice-cold ethanol. Once ethanol has evaporated, cAMP
was resuspended in 100 l of lysis buffer containing 0.3% (v/v)
Tween 20, 5 mM HEPES, and 0.1% (w/v) BSA. The amount of
cAMP generated by forskolin and its inhibition by INSL5 was
measured using a homogeneous time-resolved fluorescence
resonance energy transfer LANCE cAMP kit (PerkinElmer Life
Sciences) as per the manufacturer’s protocol.
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